Inhibikase Therapeutics (IKT) Leases (2022 - 2025)
Inhibikase Therapeutics (IKT) has disclosed Leases for 4 consecutive years, with $34918.0 as the latest value for Q2 2025.
- On a quarterly basis, Leases fell 78.68% to $34918.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $34918.0, a 78.68% decrease, with the full-year FY2024 number at $101437.0, down 54.35% from a year prior.
- Leases was $34918.0 for Q2 2025 at Inhibikase Therapeutics, down from $68719.0 in the prior quarter.
- In the past five years, Leases ranged from a high of $353250.0 in Q3 2022 to a low of $34918.0 in Q2 2025.
- A 4-year average of $202497.2 and a median of $207843.5 in 2023 define the central range for Leases.
- Peak YoY movement for Leases: dropped 29.2% in 2023, then tumbled 78.68% in 2025.
- Inhibikase Therapeutics' Leases stood at $328643.0 in 2022, then plummeted by 32.38% to $222227.0 in 2023, then tumbled by 54.35% to $101437.0 in 2024, then tumbled by 65.58% to $34918.0 in 2025.
- Per Business Quant, the three most recent readings for IKT's Leases are $34918.0 (Q2 2025), $68719.0 (Q1 2025), and $101437.0 (Q4 2024).